Earnings Call: Q3 2018

Nov 7, 2018

Ladies and gentlemen, thank you for standing by. I am Sabrina. Your Chorus Call operates Welcome, and thank you for joining the Symrise 9 months Results 2018 Conference Call. In the beginning of today's call all participants will be in a listen only mode. If any participant has difficulty hearing the conference call, please press star key followed by 0 for operator assistance. Now I'll hand over to your host of today's call, Mister Tobias Airport. Please go ahead, sir. Thank you very much Sabrina and good morning, everyone. Welcome to our analyst and investor call on the results of the 1st 9 months of this year. In today's session, our CFO, Olaf Pinger, will guide you through the results in detail. You will then have the opportunity to ask questions in the Q And A round. All corresponding materials have been published on our IR website this morning. A replay of this call will be available later today. Having said this, I now hand over to Olaf Yes. Thank you, Tobias. Ladies and gentlemen, also from my side, a very warm welcome and good morning. I think we have, again, good news to report, Sunrise has delivered very strong sales and solid earnings. Slide 2 will give you a detailed overview. Semrise continued its dynamic growth course in Q3 despite an ongoing challenging market environment. For the 9 months period, we can report a very good organic sales increase of 8.8%. Our EBITDA came in slightly below prior year at EUR 476,000,000, One reason for the slight decline in EBITDA were the ramp up costs for our investments in strategic growth initiatives namely the Diana site in Georgia, which we just opened last week, but also the OpEx for the capacity to come like the new mental production in Bushi Park or the new site in China. Our lower earnings were, however, primarily impacted by some external effect As in the first half of the year, we continue to face headwinds on the raw materials side. What started in China and visited our last year continued over the year in a shortage of further other raw materials caused by fire and hurricane related site shutdowns. We were affected ourselves at our site in Charleston with a 1 week shutdown. Suppliers of us were affected by Hurricane Michael in the Gulf area leading to new force majeure situations in the industry. Even the currently low water level of the Rhine River causes newly announced forced majeure situations, leading to additional supply shortages and therefore, higher raw material costs. In addition, exchange rates, namely the U. S. Dollar but also the Brazilian real Argentinian Peso as well as Turkish lira worked against us, especially in Q3. Despite these challenges, we kept our profitability at a healthy level. Our EBITDA margin for the 9 months period amounts to 20% and as well as in our medium term target corridor of 19% to 22%. Let turn to Slide 3 for a deep dive into our Centen Care business. The segment achieved a very good organic sales increase of 9 point 2%. Cosmetics and aroma molecules were strong growth drivers, both achieved double digit organic growth. Cosmetic ingredients or particular quick demand in Latin America and Asia Pacific, aroma molecules reported increases in all regions in the high single digit or even double digit percentage range. The fragrance division posted high single digit increases this by the tense raw material situation where we are still facing the ongoing shortage of various raw materials, which are key components for our fragrance applications. In short, the raw material situation remains tense. While we are affected by this turmoil in the raw material markets, we are strongly benefiting from our backward integration, which allows us to honor all our orders and prove again that we are highly reliable supplier for our customers. Securing supply for our customers comes along with partly higher transportation costs, as you can imagine. Segment EBITDA amounted to EUR 192,000,000. The EBITDA margin and Centene Care stood at 19.2 percent accordingly. Negotiations with our customers regarding price increases. As a result, we start to see the impact from price increases in our overall Centimeters Care growth. We will continue enforcing further price increases with our customers as we expect a further rise of raw material prices over the coming months However, with a less dynamic upward trend compared to this year. Let's turn to Slide 4. Let me also use this opportunity today to present you one of our latest projects from Centincare. It is a perfect example in how we effectively use artificial intelligence in developing fragments compositions. Developing Nu SENSE is of course, a highly creative process. However, with AI, we can innovatively support it by combining historic data on consumer preferences, along with existing fragments formulas and patterns. That way, our perfumers are guided towards completely new compositions that they have never seen before. Our first customer for this project is Oboticario from Brazil, we are currently working on 2 frequencies which we aim to bring to the market next year. This innovation quickly caught the attention of the fragrance industry related news flow over the past few days and is a good example for Sunrise ambition to be one of the innovation leaders in the industry. Another example of how we viewed Cimrat's organic growth is the latest Centincare CapEx project in Charleston U. S, which you can see on Slide 5. Only in September, we presented Hydroxide 5 Green at the Incosmetics Fair in Brazil. The multifunctional and cosmetic ingredient hydrates the skin and enhances the efficacy of active ingredients and cosmetic formulations. That's the same properties as the originally Pentilinkly call, Hydroxide 5, but the new version is based on a renewable raw material, a byproduct of sugar production derived from the sugarcane. As consumers More and more explicitly asked for natural cosmetic ingredients, hydrolyte 5 green perfectly meets this demand. Moreover, it supports our sustainability footprint. Please turn to Slide to have a look at the segment flavor. After a dynamic first half, flavor kept its high pace For the 9 months period, the segment reports double digit organic sales growth of 10.2%, including foreign exchange effect and contributions from Copel, but segment grew by 8.3% in reporting currency. Latin America delivered the strongest growth a double digit increase. This was driven by new business for beverage applications. North America also benefited from the increased demand for beverage applications. Bimi saw particularly good dynamics in Western Europe and Russia. Demand there was especially strong for applications of sweet and dairy products. Asia Pacific delivered double digit organic growth across all application areas. EBITDA for the flavor segment grew to EUR 187,000,000 compared to 1,000,000 in the prior year period. EBITDA margin came in at a solid 20.5% despite the impact from the currently still margin diluting Copel acquisition. It is worth noticing that also the flavor segment was able to pass on raw materials price increases which nevertheless has a certain diluting impact on a full cost base. Moving to Slide 7. Nutrition successfully gained momentum in the third quarter. For the overall reporting period, the segment achieved organic growth of 5.7 percent. All business units contributed to the solid development. Hat Food showed high single digit organic growth with particular good demand in Latin America. We also saw dynamic growth in food with North America posting particularly strong demand. EBITDA declined to 1,000,000. This is mainly due to weaker order intakes by 1 off major customers doing H1. In addition, we had ramp up costs for the new Diana site in the U. S, which we just opened last week. Nonetheless, EBITDA margin stands at a good 20.5%. Overall, we are optimistic for the further development of segment. Kroger delivered a strong operating performance again in Q3, driven by improved commercial execution, and recovery from this U. S. Customer destocking program. Also, our new Diana site in Georgia was opened and will start to support our superior growth ambition very soon. Please turn to Slide 8 for some more details on our new capacities there. Hershey and conscious nutrition plays a more and more important role for consumers. The market for natural and sustainable food ingredients is therefore growing. As you know, we have early on detected the trend and to dedicate investments to it. We now took another step, which is part of our current investment program dedicated to organic growth opportunities. We invested EUR 50,000,000 in the production of food ingredients, flavor, and pet food applications. The capacities are state of the art in terms of safety, efficacy and backward integration. With this investment, we also laid the foundation for further profitable growth in the U. S, the traditionally largest flavor market. For our outlook, please move to Slide 9. Based on our successful course during the year so far and a promising start into Q4, we are overall optimistic for the full year. Therefore, we raised our organic growth guidance further from above 7% to now above 8% in 2018. Which is far above the expected market growth of 3% to 4%. And we are confident to deliver the superior growth with an EBITDA margin of around 20% for the full year. We think both is very good news. Particularly in light of the ongoing headwinds from foreign exchange rates, the continuing raw material shortage and further increases in raw material prices. We are well positioned to mostly compensate those effects. Thanks to We would now like to open the floor for questions. We kindly ask you for a maximum of 2 questions. Many thanks. And may we hear the first one please? Star followed by 2. If you are using speaker equipment today, please leave the handset before making your selection. The first question is from Alexandra Trung of Morgan Stanley. Please go ahead. Good morning, and thank you for taking my questions. Just firstly, on margins, can you please provide some more detail around what you can do in the fourth quarter to get the full year guidance of around 20% margins. I guess, just taking into account that the 4th quarter is seasonally weaker, usually. Yes. Of course, I mean, I mentioned a lot around the raw materials situation, which we are managing through at the moment. This takes longer than expected. Clearly, we expected that the trial, this crisis would come to an end. So we are taking more action at the moment, especially on the price side. We acted, when all this started last year, quite quickly. So we talked basically to all customers in Centricare you see the prices coming through now also as part of the gross. But given that this raw material crisis continued with different elements, and in a mode, which definitely nobody could forecast, We will enter into further price negotiations with customers, and we are actively working on that. This is one element. I think we will, and we have said that in the past, continue to protect our margin environment And in that connection, we also will take active measures, given the shortage of many raw materials in discussion with customers when it comes to reformulations because certain raw materials are just not there. So that's part of the program. And last but not least, we had a point, where we start to look at lower margin businesses and we are ready to give this up if necessary, especially if customers are not understanding the need for further price increases. So That is all going on at the same time. And therefore, let me give you an optimistic out view that we will do a lot to come in with the around 20% by endoftheyear. Okay. Understood. So you're willing to maybe give up a little bit of volume to get to get the margins up if it's a lower margin businesses. Yes, especially if the situation is there that customers are not willing to support any price increases, which is, from our perspective, of course, no longer acceptable. And therefore, that will be one of the measures, if necessary. Okay. And then just my second question on organic growth. The 8.5% you achieved in the quarter, are you able to quantify how much of that was pricing and how much of that was volume? And then, I'm not sure if you usually provide this, but if you could also do it across the divisions? Yes. So as mentioned, we see the price elements coming through now. And therefore, in Q3, we see about 50% of the growth in the price area and 50% in volume. Inflavor, the picture is more 1 third and 2 third, 1 third price, 2 third quantity. In nutrition, it's even 3 quarter of price and 1 quarter of volume, which we see there. And in Centene Care. And this is the probably biggest change, since half year, we see 50% in price and 50% in volume. So that's about the picture for the Q3. Okay, thank you. And just a follow-up question on that pricing. Did you get any benefit from the U. S. Dollar pricing is contracted Latin America? In Q3, the picture changed a little bit compared to H1. There was a slight benefit from the U. S. Dollar environment coming in. Yes. That's more on the Centon Care side, to be more specific, flavors is more dominated by local currencies. While in Centene Care, you have, quite a good part in the U. S. Dollar based environment. But on both sides, on procurement as well as on, on the sales side. Okay. Thank you very much. The next question is from Heidi Vesterinen with Exane. Please go ahead. Hi. So first question on flavors, you talked about raw material inflation being an issue. I was quite surprised that you came in under 20%. Is there more to it than raw material inflation? Because I thought most of the issue was on the synthetic side, so Centene Care. So could you elaborate on what happened, please? Thank you. Yes, happy to do, I. So I mentioned, Coobel, of course, this is March diluting business at the moment still, which is part of the flavor, margin environment from a portfolio perspective. Maybe as an additional comment on this, if we have been quite successful with our price increases, But that's naturally only on the raw materials side. It's not on the full cost base. And therefore, we have a certain dilution on the margin side in such an environment where prices are going fast in vanilla and citrus. So That is a little bit more explanation why we see a slight margin dilution in Flavors. It's the same environment. We will continue to, negotiate on the price side and protecting the business will be an important measure of labor also going forward. And then the next question on margins. Would you be able to quantify the ramp cost and the hurricane effect and basically, you know, one off type issues that you saw in Q3? And as we go into 2019, because these ramp costs should be behind us, can we expect margins to increase next year? So the ramp up and hurricane environment, I would qualify as around EUR 5,000,000, which we have seen. You know that we have an investment program, and there are a number of larger projects in the pipeline at the moment. We are heavily investing into organic growth opportunities which we have. They are all going in the right direction and the profitable growth environment. And, from that perspective, I think we are doing the right things at the moment. And that's across the board. Is it too early to comment on 2019 margins? It's logically, it would make sense that if you're ramping in higher margin areas, the margin should increase, but if it gets too early because It's a little bit too early. One reason is that the, harvesting season is still ongoing. The vanilla price situation is still ongoing and not fully clear yet where it will go. So that is from the flavor perspective a little bit too early, to guide. And on the Centene Care side, as mentioned, we are not through this raw material crisis at the moment. I think we have a better position given that we have our backward integration and we are using this situation actively. I think it's very positive that we can supply in this situation and honor our orders. Just on my desk, I have, three letters from suppliers, declaring force majeure over the last few weeks. So It's, if you ask our procurement people, they will probably tell you it's a perfect storm situation at the moment, but it's a storm and a storm will go be over at some point and then, things should normalize. But it's a little bit too early to guide for next year. Give him where we are at the moment. Thank you. Welcome. The next question is from Patrick Lambert of Raymond James. Please go ahead. Hi good morning. I think all my questions have been been asked. Just maybe just one follow-up on what was the specific impact on Charlesten week of disruption just to understand the 220 basis point margin pressure on differential on Q3? Thanks. So, the hurricane of course has an impact, we are basically sold out with all the materials. If you have to shut down and, this was basically without causing any damage, but it was forced by the governor, and we we had to give up this 1 week. If you are sold out, basically, you're missing, this quantity and you cannot sell it. That's basically the situation. I would quantify this around 1,000,000 impact from this hurricane. Do you think you can somehow recover that in Q4 again, if you are sold out and the quantity is basically, fully absorbed. If you miss a week, you cannot recover this. That's not possible. I would also mention the foreign exchange site again. We had seen extremely strong volatility, especially in August, in Argentina, in Brazil, in Turkey, These were transactional effects that you, of course, cannot foresee in such a situation the magnitude there was around 3,000,000 just out of transaction hitting the results situation. For the group, right? That's for the group, yes. And as mentioned multiple times, this raw material situation is there. And there's a well known time delay before you can recover, these kind of price movements on the raw materials side. So I think we need a little bit of time, and I can assure you that we are continuing to push on the price increase side plus all the other measures, which I mentioned, to protect our margin environment. The next question is from Thomas Buhoda of Societe Generale. Please go ahead. Yes. Good morning, gentlemen. I have two questions as well. Coming back to the startup costs, and looking into 2019 again, I'm sorry for that. But you were in the midst in the midst of a of a bigger program. So I'm just wondering thinking of the startup costs sequentially Is it fair to assume that start up costs will be lower year over year in 2019? Or they actually could increase year over year going into 2019. Could you give an indication on that, please? Yes, good morning Thomas. No, I don't expect that they will increase further. I think we will have some ramp up costs also next year, the getting closer to the Mentor capacity in Bushey Park, also the China site as well, on the development, and we will have to hire the first people now, to run this facility. So that will bring some extra OpEx, startup cost, but it should not be more than they have seen in 2018. From today's perspective. Perfect. This is very clear. And the second question coming back again to the emerging markets. I mean, you already mentioned this transactional or transactional issue but I'm still wondering what should we think about LatAm? You have 25% underlying growth in Q3. My question is, is this a kind of a same situation like in with the raw materials where the currencies devalue, you you are losing profitability and you need time to catch up. So is this still an effect? Which we should be seeing going forward that you recovered the profitability in LatAm or are you are you basically increasing your prices in local currency on a in a very timely manner? I mean, inflationary environments, you need to act, of course, on an ongoing basis, and we do that, of course. But this has nothing to do when it comes to the raw materials situation. That's across the globe and we take action across the globe to compensate for raw material price increases. So that is not so much linked to the LatAm situation. Keep in mind that the LATAM business for us is around 300,000,000. So 12, 13% of turnover for us, that is not the biggest impact. And we have seen very good volume growth in LatAm over the 1st 9 months so far. So the growth in LatAm is 2 fold. It's, part of the inflationary environment. But it's also very much driven by volume growth, which we enjoy in this region. This is very helpful. Thank you. Welcome. The next question is from Patrick Schmidt of Warburg Research. Please go ahead. Hi, thanks for taking my question. My first one was already been answered. So I continue with the second one. You mentioned your great R and D developments with IBM Research and also mentioned that you're strengthening your innovation power looking at the industry, you have, let's say, one of the lowest R and D costs block in terms of your percentage of sales. Can we expect this to change and that you have maybe slightly higher R and D costs going forward? Or is that kind of a non event? No, we are pretty comfortable with the R and D spend, which we have. So you should expect that on the similar level as in the past. I think, as you always like to say, R and D success is not a question of money. I think it's the way you do it, And, this project, which we have just done this IBM is a very good example. How we invest and we really enter into the future. Just this week, we will be part of an IBM conference in Switzerland where we present this as one of the major development projects also from an IBM perspective. So, dedicated R and D spend, which we do here, but not just the ambition that we need to spend more at the end of the day. To be successful in our game. The next question is from Daniel Chung with Redburn. Please go ahead. My first one is just to understand, dynamics in Europe, as I can see, that organic growth has dropped to 1.9%. So just it'd be helpful just to elaborate on what's happening there. And my second question is, for the organic growth that we've seen in LatAm and APAC, which has been pretty strong, how much is this growth is being offset by the weakness in FX? So I think the, the situation in Europe is nothing, specific. I think you have seen very strong growth in North America and Asia Pacific. And that's where we are primarily also investing at the moment. I wouldn't hint to anything specific that Europe is coming out weaker, except that we are really pushing in areas where we see also future growth. That drive the higher numbers in Asia Pacific And North America, where we also in comparison to last year, but not that strong. And now, it's coming back, basically. On the LatAm question, I cannot really give you the perfect answer on the growth, which is FX related, therefore, the universe is just too complex with U. S. Dollar pricing elements in there. This, as I mentioned, a good volume grows, And at the same time, a little bit of the organic growth is influenced by Latin America's currency developments. But it's, again, as a proportion to our total business, not a substantial impact on the gross profile. Okay. Thank you very much. Welcome. The next question is from Jeff Hayyer of UBS. Please go ahead. Hi, good morning gentlemen. Thank you for taking my questions. Just two quick questions. First of all, the 8% guidance you've given for the full year organic growth. Does that include any element of trimming low margin products? And secondly, can you just comment on the exit EBITDA margin in the quarter was it higher or lower than the average for the quarter? Sorry, I didn't get the second part. So the EBITDA margin for the group in September as you moved into Q4, was it lower or higher than the average for the quarter? It's just the month of September. Yes. I think you know that we are not commenting on months the basis that would be a little bit more stretched. What I'm trying to understand is as you move into the 4th quarter, how successful the price increases being in lifting the margin given that obviously the lag between price increases and offsetting that margin pressure. That's difficult to answer. What we can tell you is that we had a very, very good start into the fourth quarter. So I think that's what I can give you at the moment. Commenting on EBITDA margin profiles month by month is very, very difficult. You have overlaps between months. So I think sticking to the quarter is the right thing to do. In this environment. Yes. So, Jeff, on the first part, the guidance includes basically our expectation for the full year. And includes also the measures, which we are taking at the moment to protect our margin environment. Okay. Thank you. Welcome. The next question is from Gunther Sakhman with Bernstein. Please go ahead. Hi, good morning. Two questions. Can you firstly comment on any changes you've seen in competitive behavior after the consolidation in the industry by your competitors, particularly on the flavor side of the business. And the second one is, you already indicated that around Citro, we are still in a crisis situation. Can you just confirm if you expect that to continue on an unchanged level for the remainder of Q4. And then, tied in with the raw materials as well, can you quantify the impact you've seen on your costs from the lower water levels on the Rhine River? So, on the first part, the competition and any change there related to recent acquisitions, No. I am there's nothing which I could really mention. There's no, discussion in this regard in our, company but there's really a different dynamic related to these acquisitions. So that's the first one. I think the fact that we are growing, the fastest and still continue to grow. And that's our ambition faster than anybody else. Is a good indicator that we are not so much worried about any movements on the M and A side at the moment. We clearly focus on organic growth, and that's what we are investing. On the trial side, I think BASF We'll come back. That's the incident that we saw in Ludwigshafen at the end of October last year. So I think they are starting to ramp up. The surprising part is that there are many, many more incidents, we have seen this China situation where all of the sudden production capacity was shut down for environmental reasons. This will not come back. The situation in India, the 2 fires at, preview and DRT, they will be resolved at some point next year. That's the expectation. But Harry can shut downs, now the Rhine River of water level, leading to further shortages, they will all go away. I I cannot quantify them, on the incident. But it's the situation which we need to steer through at the moment, and it goes clearly beyond what was initially owned this CIT file and BASF. And for you, because it's hard to see what inventory levels you're working through, especially around your German production facilities. Can you just comment on when you started to see an impact on your costs from the Rhine River water levels. And if you would agree that this has continued year to date, I. E. At least a month and a half into Q4. I mean, the situation is in discussion for a few weeks now that, ships cannot be loaded as in the past. They are running with limited volume. The more important piece here is that because of this, certain production apparently cannot take place. And therefore, we get informations from suppliers that certain material is just not available. So again, a situation where we need to find replacement solutions to cover And basically, still be in a position to honor all the orders, which we're getting. And we are very proud of this situation, but we can supply. And one reason for that is our very established backward integration. Where we are an active player in the market on the other side. But again, excuse me, if I cannot quantify just the Rhine River level cost impact. Okay. Thank you. The next question is from Charlie Craig of Citi. Please go ahead. Good morning, gentlemen. Thank you for the presentation. Most of my questions asked, but just one. And if you'd look at Nutrition, could you quantify the ex pro B organic growth in the quarter? Just the quarter or the 9 months? Just could you know it was sort of it was 10% for the quarter. I was wondering what it looked like ex Probi just for the quarter. Give me a second. It's a bit of, tricky. Let let us follow-up on this one. Okay. Yeah. Thank you. Okay. The next question is from Neut Hinkel of Equinix Bank. Please go ahead. Hello? Mister Hinkle, your line is open. Please go ahead. He dropped. Yes, sorry. The next question is from isha Sharma of MainFirst. Please go ahead. My, I just have one question. So, there is you have reported strong growth in cosmetic ingredients in aroma molecules in Centimeters Care. And also beverages and flavors. I assume, or I understand that these are high margin businesses And then we have seen this contraction in the EBITDA margin. I also understand this is because of the raw material in patient, the cramp, of course, but would be really great if you could give us a little bit of guidance going into Q4 in 2019 as to the situation improves, would you assume similar growth in high margin businesses and then see a little bit of, relief in the other areas that causing this contraction in the margins? Thanks. Yes. So as I said, we are very comfortable, and that's why we increased our, gross guidance to more than 8% now. So, we're enjoying a very, very nice growth environment across all segments at the moment. And the fact that we increased the guidance is, I think, perfect indicator that, we believe to deliver on this, also in Q4. The margin compression which we have at the moment is explained with some extraordinary items, foreign exchange wise, startup cost wise, specifically with raw materials. And I think I've commented on the actions which we are taking to, protect our market environment. It's, at the moment, at least, it's an ambitious environment, It's a demanding environment, but we are steering through this. And I think given our positioning our backward integration, we have good reasons to believe that we will be able to protect our margin environment even if it's challenging, but around 20% EBITDA guidance is out there. And that's what we want to deliver. The next question is from Patrick Lambert of Raymond James. Please go ahead. Thanks. Just a quick follow-up. FX for Q4, have you done the exercise of try to quantify the impact on your top line. You get minus 3 in Q3. U. S. Dollars a bit better, Brazilians a bit better, but still some some other currencies are are still as bad as is in Q3. So if you had some calculations to share with us? Yes. So the expectation is that we will end the year with an impact somewhere between 4 a half 5%. So it should further improve. Coming from the 5 point, please. I think it was. Yes. For the 1st 9 months. So you should see less headwinds for the rest of the year with the full year guidance of 4.5% to 5% Okay. Thank you. You're welcome. The next question is from Liz Cohen of Wazeevi. Please go ahead. Thank you. Good morning, gentlemen. Just a follow-up from an earlier question, please. On flavors, you said you've been quite successful on achieving price increases on the raw material side, but not on the full cost base. Can you just elaborate a little bit more there in terms of, let's say, non raw material cost headwinds you're seeing? And then the outlook for inflation there? Thank you. Yes, thank you for the question. And I think it's very important. Except for the wrong situation, the cost situation is fully under controlled. We are not seeing any dynamic cost developments. So it's really around the raw material situation. And naturally, you get the price increases on the raw material price increases, through, but the rest is then always a question of time. And there's also one element, which I'd like to mention that Boston Flavors, we have a portfolio of activities, some with higher margins, others with lower margins and some products come with higher raw material proportions. So in this environment portfolio effect is also part of the margin compression, which we see at the moment. Again, the message is really we are working actively on protecting, the margin environment there. And so far, I think we have been very successful in passing through price increases to customers in flavors where the price environment started much earlier than in Centric Care, as you might remember. Yes, that's great. Thank you, Olaf. Welcome. Okay. No more on the line, in the queue, ladies and gentlemen, we are coming to the end of today's conference call. I would like to hand over to Ola for final remarks. Please go ahead Ola. Yes. So, one final, before we conclude today, just a reminder on our announcement during the first quarter this year regarding our reporting for next year in line with competition and also clients We will move to trading updates only for Q1 and Q3. And we take this step to inform you more promptly towards the quarter end and to further emphasize this long term nature of our business. I just would like to give this reminder that this will come for next year. And this, this being mentioned, I'm looking forward, we are looking forward to seeing you obviously, some of you doing our upcoming investor events this month, speed in London, in Edinburgh, or in Paris. So with that, we would like to conclude today's call. Thank you very much for your, attention and participation. Goodbye. Thank you. Bye. Thank you for joining, and have a pleasant day. Goodbye.